The FDA has issued an EUA for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
- ACEP Statement on Monoclonal Antibody Infusion
- ACEP's Clinical Summary of Bamlanivimab
ACEP Infographic - Should you consider using Bamlanivimab to treat your COVID patient? - FDA's Letter of Emergency Use Authorization (EUA)
- FDA Casirivimab and Imdevimab (administered together) Letter of Authorization (PDF)
- Fact Sheet for Health Care Providers EUA of REGEN-COVTM (casirivimab and imdevimab)
- CMS: Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction
- Bamlanivimab Baseball Card
- Casirivimab + Imdevimab Baseball Cards
From Eli Lilly and Company
- Fact Sheet for Health Care Providers EUA of Bamlanivimab
- Fact Sheet for Patients, Parents and Caregivers EUA of Bamlanivimab
- Guía informativa para pacientes, padres y cuidadores Autorización de uso de emergencia (EUA) de bamlanivimab
- Lilly Bamlanivimab Antibody Playbook
From Regeneron
- Casirivimab and Imdevimab Letter and Resources (PDF)
- Important Prescribing Information for REGEN-COV™ (casirivimab and imdevimab)
